As of July, 2020, the ongoing pandemic of coronavirus diseases 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously 2019-nCoV) has caused more than 10.3 million human infections, with more than 506,000 deaths worldwide according to the World Health Organization.Although the Food and Drug Administration has authorized emergency use of remdesivir for COVID-19 treatment in the US, the need for safe and effective antiviral drugs against SARS-CoV-2 remains urgent and unmet.25-Hydroxycholestrol (25HC) is the product of cholesterol oxidation by the enzyme cholesterol-25-hydroxylase, encoded by CH25H gene & in innate immunity, its expression is induced in macrophages and dendritic cells in response to various toll-like receptor ligands & interferon (IFN).To examine the 25HC increase in COVID-19 patients, we studied the serum concentrate of 25HC in SARS-CoV2-infected intranasally hACE2 mice & all animals had higher serum concentrate of 25HC than the control group.Intranasal infection of SARS-CoV-2 mouse-adapted strain MASCp6 also led to the upregulated mRNA level of CH25H in the lung tissue from the infected mice compared with the that from the control animals. Most importantly, over-expression of CH25H resulted in a significant reduction in SARS-CoV-2 viral genome in Vero cells.Collectively, these in vitro & in vivo results further supported the antiviral role 25HC during SARS-CoV-2 infection with no adverse effects.